SCHEMBL10172340

SCHEMBL10172340

Bc1cc(B)cc(C)c1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3625653 0.92
Water SCHEMBL27812755 0.89 ALDH1A1 (0.44)
SCHEMBL11921051 0.78
SCHEMBL14275986 0.78
SCHEMBL13654799 0.78
SCHEMBL12269087 0.78
SCHEMBL12022802 0.78
SCHEMBL25062001 0.74 ALDH1A1 (0.48)
SCHEMBL13083359 0.74 HTT (0.33)
SCHEMBL17796960 0.74 POLB (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1889642-B1 Cosmetic compositions combining a C-glycoside derivative and a N-acylaminoamide derivative OREAL (FR) 2019-05-08 EP disclosed
US-20180064824-A1 CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY MERCK SHARP & DOHME CORP. (US) 2018-03-08 US disclosed
US-9745355-B2 Binding-site modified lectins and uses thereof SMARTCELLS, INC. (US) 2017-08-29 US disclosed
US-9579391-B2 Conjugate based systems for controlled drug delivery SMARTCELLS, INC. (US) 2017-02-28 US disclosed
US-20170022262-A1 CRYSTALLINE INSULIN-CONJUGATES SMARTCELLS, INC. (US) 2017-01-26 US disclosed
US-9463249-B2 Crystalline insulin-conjugates SMARTCELLS, INC. (US) 2016-10-11 US disclosed
US-20160193351-A1 CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY SMARTCELLS, INC. (US) 2016-07-07 US disclosed
US-9265838-B2 Conjugate based systems for controlled drug delivery SMART CELLS, INC. (US) 2016-02-23 US disclosed
US-20150265717-A1 CONJUGATE BASED SYSTEMS FOR CONTROLLED DRUG DELIVERY SMARTCELLS, INC. (US) 2015-09-24 US disclosed
US-9114176-B2 Exogenously triggered controlled release materials and uses thereof SMARTCELLS, INC. (US) 2015-08-25 US disclosed
US-7419970-B2 Aging resistance; controlling skin elasticity; example: ethyl {2-[acetyl(3-trifluoromethyl-phenyl)amino]-3-methylbutyrylamino}acetate; of slowing down the degradation activity of the elastic fibres of the intercellular spaces, may make it possible to reduce this phenomenon of accelerated ageing of skin L'OREAL (FR) 2008-09-02 US disclosed
EP-1743900-B1 Organic compounds, organometallic complexes, organic electroluminescent display devices using the complexes and method for preparation of the devices SAMSUNG SDI CO LTD (KR) 2008-08-13 EP disclosed
EP-1889642-A2 Cosmetic compositions combining a C-glycoside derivative and a N-acylaminoamide derivative L'OREAL (FR) 2008-02-20 EP disclosed
US-20080014230-A1 Cosmetic compositions combining a C-glycoside derivative and an N-acylamino amide derivative L'OREAL (FR) 2008-01-17 US disclosed
US-20080014230-A1 Cosmetic compositions combining a C-glycoside derivative and an N-acylamino amide derivative L'OREAL (FR) 2008-01-17 US disclosed
EP-1269988-B1 Cosmetic or dermatological composition comprising acylaminoamide derivatives OREAL (FR) 2007-12-05 EP disclosed
EP-1626976-B1 OLEFIN POLYMERIZATION CATALYST SYSTEM EXXONMOBIL CHEM PATENTS INC (US) 2007-10-17 EP disclosed
US-7282586-B1 Dipyridine-based compound and the use thereof LUMINESCENCE TECHNOLOGY CORP. (TW) 2007-10-16 US disclosed
EP-1275372-B1 Cosmetic or dermatological composition comprising a N-acylaminoamide derivative and a metalloproteinase inhibitor OREAL (FR) 2007-06-13 EP disclosed
EP-1399113-B1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING N-ACYLAMINOAMIDE DERIVATIVES OREAL (FR) 2007-03-21 EP disclosed